A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cell Line, Tumor
/ transplantation
Drug Evaluation, Preclinical
Drug Resistance, Neoplasm
/ drug effects
Drug Synergism
Female
Humans
Imiquimod
/ pharmacology
Indoles
/ pharmacology
Killer Cells, Natural
/ drug effects
Lymphocytes, Tumor-Infiltrating
/ drug effects
Male
Melanoma, Experimental
/ drug therapy
Membrane Glycoproteins
/ agonists
Mice
Mutation
Natural Killer T-Cells
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Skin Neoplasms
/ drug therapy
Sulfonamides
/ pharmacology
T-Lymphocytes
/ drug effects
Toll-Like Receptor 7
/ agonists
BRAF inhibitor resistance
T cell and NK cell immunity
melanoma
targeted therapy
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
04
07
2019
revised:
25
09
2019
accepted:
31
10
2019
pubmed:
9
11
2019
medline:
15
2
2020
entrez:
9
11
2019
Statut:
ppublish
Résumé
Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human melanoma. In our study, we used the transplantable D4M melanoma mouse model with the BRAF
Identifiants
pubmed: 31702822
doi: 10.1002/ijc.32777
pmc: PMC7003881
doi:
Substances chimiques
Indoles
0
Membrane Glycoproteins
0
PLX 4720
0
Sulfonamides
0
Tlr7 protein, mouse
0
Toll-Like Receptor 7
0
Braf protein, mouse
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1420Subventions
Organisme : Austrian Science Fund FWF
ID : T 737
Pays : Austria
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
J Clin Invest. 2012 Feb;122(2):575-85
pubmed: 22251703
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Invest Dermatol. 2012 Jan;132(1):163-9
pubmed: 21850019
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Oncoimmunology. 2018 Apr 18;7(8):e1450127
pubmed: 30221038
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Immunotherapy. 2014;6(10):1085-95
pubmed: 25428647
Oncoimmunology. 2019 Apr 19;8(7):1601480
pubmed: 31143525
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
Cancer Immunol Res. 2014 Nov;2(11):1044-50
pubmed: 25183499
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
Melanoma Res. 2016 Aug;26(4):409-12
pubmed: 27138458
J Immunol. 2004 Sep 1;173(5):3051-61
pubmed: 15322165
Oncoimmunology. 2017 Nov 6;7(2):e1392426
pubmed: 29308322
Nat Med. 2019 Jun;25(6):936-940
pubmed: 31171879
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
J Clin Oncol. 2011 Aug 1;29(22):3085-96
pubmed: 21383288
J Clin Invest. 2013 Mar;123(3):1371-81
pubmed: 23454771
Am J Clin Dermatol. 2004;5(6):453-8
pubmed: 15663342
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Int J Cancer. 2009 Apr 1;124(7):1594-604
pubmed: 19089914
Cancer Res. 2017 Apr 1;77(7):1599-1610
pubmed: 28202513
J Invest Dermatol. 2013 Jun;133(6):1601-9
pubmed: 23321925
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Arch Dermatol. 2003 Mar;139(3):273-6
pubmed: 12622616
Int J Cancer. 2013 Oct 1;133(7):1653-63
pubmed: 23526263
Oncotarget. 2017 Apr 11;8(15):24932-24948
pubmed: 28212561
Oncoimmunology. 2016 Oct 14;5(12):e1238557
pubmed: 28123875
Cell. 2015 Sep 10;162(6):1271-85
pubmed: 26359985
Mol Cancer Ther. 2014 Dec;13(12):2769-83
pubmed: 25385327
Oncogene. 2008 Oct 6;27(45):5944-58
pubmed: 18836475
Cancer Res. 2014 Dec 15;74(24):7298-308
pubmed: 25351955
J Invest Dermatol. 2009 Nov;129(11):2676-85
pubmed: 19516264
Nat Rev Cancer. 2012 Apr 05;12(5):349-61
pubmed: 22475929
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Curr Top Microbiol Immunol. 2016;395:115-45
pubmed: 26025472
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
J Clin Oncol. 2013 Feb 1;31(4):499-506
pubmed: 23248252
J Immunol. 2006 Jan 15;176(2):905-13
pubmed: 16393975
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Pigment Cell Melanoma Res. 2014 May;27(3):495-501
pubmed: 24460976
Cancer Immunol Res. 2014 Jul;2(7):643-54
pubmed: 24903021
Oncoimmunology. 2016 May 31;5(7):e1189051
pubmed: 27622045
Oncoimmunology. 2012 Dec 1;1(9):1476-1483
pubmed: 23264894
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Cancer Res. 2012 Dec 15;72(24):6325-32
pubmed: 23222302
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Nat Med. 2019 Jun;25(6):929-935
pubmed: 31171876
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Front Immunol. 2013 Oct 28;4:346
pubmed: 24194739
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Cancer Res. 2014 Jun 15;74(12):3205-17
pubmed: 24736544
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859